Skip to main content

LIVE

OverviewAnalystsInstitutionalElite HoldersEarningsNews
ALDX

Aldeyra The

ALDX

NASDAQ·Healthcare·Biotechnology·Mkt cap $89.3M

$1.48

▲ 0.00%

P/E

-3.82

Mkt Cap

$89.3M

52-Wk Range

$1.07–$5.93

52-Week Range

$1.07 - $5.93

P/E

-3.82

Fwd P/E

-4.35

Beta

1.19

Div Yield

0.00%

Avg Vol

1.2M

Shares Out

60.2M

Mkt Cap

$89.3M

Price action

Price chart

Down 74.0% over the trailing year

Total returns

Price performance

Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.

Why we rate it this way

The thesis at a glance

Bull and bear case · plain-English context across the five lenses we evaluate.

▲

Bull Case

3 reasons

  • Proprietary RASP modulation platform with first-mover advantage in reactive aldehyde targeting
  • Diversified pipeline spanning ophthalmology and systemic immunology with multiple Phase II/III programs
  • Strategic partnerships and licensing agreements expanding development capabilities and reducing capital requirements
▼

Bear Case

1 risk

  • Average volatility.

Growth

Stable outlook

Reproxalap Phase III trial completion and potential FDA approval for large dry eye disease market

Value

Deep value opportunity - significant discount to Biotech & Therapeutics peers

Momentum

Weak

-14.9% over 3m

Quality

Loss-making

Mixed fundamentals

Dividend

None

No dividend

Earnings track record

Recent earnings results

AI-summarized recap of last quarter, plus the surprise on every print.

Next: Nov 4, 2026

“
Q3 26 RECAP

AUG 6, 2026

Reported EPS of -$0.09 vs -$0.09 consensus (-2.9% surprise).

EPS miss

EPS surprise · last 4Q

0 of 1 beats

Estimate

Actual

Q3 26

-2.9%

Revenue trend · last 8Q

—

—

—

—

—

—

—

—

Q3 24

Q4 24

Q1 25

Q2 25

Q3 25

Q4 25

Q1 26

Q2 26

$0

$0

$0

$0

$0

$0

$0

$0

Margins · last 8Q

No margin history available.

View full earnings history →

Wall Street consensus

1 analyst · 0% Buy

Live ratings and price targets aggregated across covering analysts.

Buy

0%

Hold

1

100%

Sell

0%

Median Price Target

—

Latest: HC Wainwright · Mar 18, 2026

View full analyst page →

vs Industry

How ALDX stacks vs Biotechnology

Stock metrics vs industry averages. Green = better than industry.

Industry comparison data unavailable for this stock.